[HTML][HTML] Postmarketing surveillance study of erlotinib in Japanese patients with non–small-cell lung cancer (NSCLC): an interim analysis of 3488 patients …
K Nakagawa, S Kudoh, Y Ohe, T Johkoh… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
K Nakagawa, S Kudoh, Y Ohe, T Johkoh… - Journal of Thoracic …, 2012 - europepmc.org
Methods All patients with recurrent/advanced NSCLC receiving erlotinib in Japan were
enrolled (December 2007-October 2009). During the 12-month observation period, adverse …
enrolled (December 2007-October 2009). During the 12-month observation period, adverse …
[PDF][PDF] Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC)
K Nakagawa, S Kudoh, Y Ohe, T Johkoh… - Journal of Thoracic …, 2012 - academia.edu
Methods: All patients with recurrent/advanced NSCLC receiving erlotinib in Japan were
enrolled (December 2007–October 2009). During the 12-month observation period, adverse …
enrolled (December 2007–October 2009). During the 12-month observation period, adverse …
[HTML][HTML] Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients …
K Nakagawa, S Kudoh, Y Ohe, T Johkoh, M Ando… - Journal of Thoracic …, 2012 - jto.org
Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …
[引用][C] Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)
K NAKAGAWA - J Thorac Oncol, 2012 - cir.nii.ac.jp
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung
cancer (NSCLC) : an interim analysis of 3488 patients (POLARSTAR) | CiNii Research CiNii …
cancer (NSCLC) : an interim analysis of 3488 patients (POLARSTAR) | CiNii Research CiNii …
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)
K Nakagawa, S Kudoh, Y Ohe… - Journal of thoracic …, 2012 - pubmed.ncbi.nlm.nih.gov
Introduction Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non-small-cell lung cancer (NSCLC) receiving erlotinib. To …
Japanese patients with non-small-cell lung cancer (NSCLC) receiving erlotinib. To …
[引用][C] Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients …
K Nakagawa, S Kudoh, Y Ohe, T Johkoh… - Journal of Thoracic …, 2012 - cir.nii.ac.jp
Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung
Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR) | CiNii Research CiNii …
Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR) | CiNii Research CiNii …